Immunocore FY2024 EPS Estimate Increased by Leerink Partnrs

Immunocore Holdings plc (NASDAQ:IMCR) – Research analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of Immunocore in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($1.48) per share for the year, up from their previous estimate of ($2.20). The consensus estimate for Immunocore’s current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Immunocore’s Q4 2024 earnings at ($0.93) EPS and FY2025 earnings at ($2.59) EPS.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.98% and a negative net margin of 15.87%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the company earned ($0.59) earnings per share.

IMCR has been the subject of a number of other research reports. Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Morgan Stanley lowered their target price on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Finally, Oppenheimer reissued an “outperform” rating and issued a $89.00 target price (up from $87.00) on shares of Immunocore in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $73.73.

Immunocore Price Performance

Shares of IMCR stock opened at $34.69 on Friday. The firm’s 50 day moving average price is $32.64 and its two-hundred day moving average price is $39.52. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17. The stock has a market cap of $1.74 billion, a PE ratio of -36.52 and a beta of 0.72. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98.

Institutional Trading of Immunocore

Several institutional investors and hedge funds have recently bought and sold shares of IMCR. Primecap Management Co. CA grew its stake in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after buying an additional 520,950 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Immunocore by 7.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock worth $13,297,000 after purchasing an additional 29,689 shares during the period. GSA Capital Partners LLP acquired a new position in Immunocore during the third quarter worth approximately $406,000. Crossmark Global Holdings Inc. bought a new stake in Immunocore in the third quarter valued at approximately $866,000. Finally, Assetmark Inc. lifted its position in shares of Immunocore by 6.5% in the third quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after buying an additional 1,878 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.